Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vi… Read more
Pfizer Limited - Asset Resilience Ratio
Pfizer Limited (PFIZER) has an Asset Resilience Ratio of 93.68% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Pfizer Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Pfizer Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹20.47 Billion | 48.4% |
| Short-term Investments | ₹19.15 Billion | 45.28% |
| Total Liquid Assets | ₹39.61 Billion | 93.68% |
Asset Resilience Insights
- Very High Liquidity: Pfizer Limited maintains exceptional liquid asset reserves at 93.68% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Pfizer Limited Industry Peers by Asset Resilience Ratio
Compare Pfizer Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
PINK:NVSEF |
Drug Manufacturers - General | 0.13% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 7.18% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
Annual Asset Resilience Ratio for Pfizer Limited (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Pfizer Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 56.62% | ₹27.81 Billion | ₹49.11 Billion | +8.80pp |
| 2024-03-31 | 47.82% | ₹20.22 Billion | ₹42.29 Billion | +2.04pp |
| 2023-03-31 | 45.79% | ₹18.32 Billion | ₹40.01 Billion | +5.25pp |
| 2022-03-31 | 40.54% | ₹15.81 Billion | ₹39.01 Billion | +8.66pp |
| 2021-03-31 | 31.88% | ₹10.41 Billion | ₹32.66 Billion | -17.70pp |
| 2020-03-31 | 49.58% | ₹21.84 Billion | ₹44.05 Billion | +2.02pp |
| 2019-03-31 | 47.55% | ₹18.74 Billion | ₹39.40 Billion | +0.81pp |
| 2018-03-31 | 46.75% | ₹17.25 Billion | ₹36.90 Billion | +1.28pp |
| 2017-03-31 | 45.47% | ₹14.87 Billion | ₹32.71 Billion | +45.32pp |
| 2016-03-31 | 0.15% | ₹43.26 Million | ₹29.14 Billion | +0.15pp |
| 2012-03-31 | 0.00% | ₹500.00K | ₹15.76 Billion | -39.68pp |
| 2011-03-31 | 39.68% | ₹5.50 Billion | ₹13.86 Billion | +8.76pp |
| 2010-03-31 | 30.92% | ₹3.72 Billion | ₹12.03 Billion | +8.33pp |
| 2009-03-31 | 22.59% | ₹2.48 Billion | ₹10.98 Billion | -30.54pp |
| 2008-03-31 | 53.13% | ₹4.61 Billion | ₹8.67 Billion | +42.82pp |
| 2007-03-31 | 10.31% | ₹666.73 Million | ₹6.47 Billion | -1.16pp |
| 2006-03-31 | 11.47% | ₹660.82 Million | ₹5.76 Billion | -1.92pp |
| 2005-03-31 | 13.39% | ₹699.09 Million | ₹5.22 Billion | -- |